Pro zobrazení tohoto obsahu je třeba být přihlášen.
Categories for Uncategorized
PEGCRISANTASPASE AND VENETOCLAX COMBINATION IS HIGHLY EFFECTIVE AGAINST ACUTE MYELOID LEUKEMIA (AML), MECHANISTICALLY DRIVEN SYNERGISM BETWEEN GLUTAMINE DEPLETION AND BCL-2 INHIBITION
26 ledna, 2021 8:53 pmAuthor(s): A. Emadi1, R. Gartenhaus, B. Bhandary, H. Kaizer, E. Chang, et al. EHA Library. Emadi A. Jun 15, 2019;...
THE SINGLE-CELL ATLAS OF DRIVER MUTATIONS IN AML
26 ledna, 2021 8:53 pmAuhor(s): K. Morita, F. Wang, K. Jahn, Y. Yan, R. Durruthy-Durruthy, et al. EHA Library. Morita K. Jun 15, 2019;...
DECIPHERING THE ROLE OF RUNX1 ISOFORMS IN THE DEVELOPMENT OF TRANSIENT ABNORMAL MYELOPOIESIS
26 ledna, 2021 8:53 pmAuthor(s): S. Gialesaki, M. Labuhn, D. Brauer-Hartmann, S. Matzk, F.-J. Struwe, et al. EHA Library. Gialesaki S. Jun 14, 2019;267347;...
Co je nového v léčbě AML?
26 ledna, 2021 8:53 pmVe dnech 13.–16. června 2019 se v Amsterdamu konal 24. kongres Evropské hematologické společnosti, který přinesl komplexní přehled novinek z oblasti onkologické a neonkologické...
BLINATUMOMAB FOR MINIMAL RESIDUAL DISEASE (MRD) IN ADULTS WITH BCELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA (BCPALL): MEDIAN OVERALL SURVIVAL (OS) NOT REACHED AT 5 YEARS FOR COMPLETE MRD RESPONDERS
26 ledna, 2021 8:53 pmAuthor(s): Nicola Goekbuget, Hervé Dombret, Gerhard Zugmaier, Massimiliano Bonifacio, Carlos Graux, et al. EHA Library. Goekbuget N. Jun 16, 2019;...
REAL-WORLD RESULTS ON CD19 CAR T-CELL FOR 60 FRENCH PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA INCLUDED IN A TEMPORARY AUTHORIZATION FOR USE (ATU) PROGRAM
26 ledna, 2021 8:53 pmAuthor(s): C. Thieblemont, S. Legouill, R. Di Blasi, G. Cartron, F. Morschhauser, et al. EHA Library. Thieblemont C. Jun 16,...
PET AFTER 2 CYCLES OF ABVD IN PATIENTS WITH EARLY-STAGE FAVORABLE HODGKIN LYMPHOMA TREATED WITHIN THE PHASE 3 GHSG HD16 STUDY
26 ledna, 2021 8:53 pmAuthor(s): M. Fuchs, H. Goergen, C. Kobe, H. Eich, C. Baues, et al. EHA Library. Fuchs M. Jun 15, 2019;...
FIVE-YEAR FOLLOW-UP OF PATIENTS RECEIVING IBRUTINIB FOR FIRST-LINE TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA
26 ledna, 2021 8:53 pmAuthor(s) A. Tedeschi, J. Burger, P. M. Barr, T. Robak, C. Owen, et al. EHA Library. Tedeschi A. Jun 14,...
THE BRAF INHIBITOR VEMURAFENIB COMBINED WITH RITUXIMAB PRODUCES A HIGH RATE OF DEEP AND DURABLE REMISSIONS IN RELAPSED OR REFRACTORY HAIRY CELL LEUKEMIA: UPDATED RESULTS OF A PHASE-2 TRIAL
26 ledna, 2021 8:53 pmAuthor(s): E. Tiacci, L. De Carolis, E. Simonetti, F. Zaja, M. Capponi, et al. EHA Library. Tiacci E. Jun 14,...
OBINUTUZUMAB PLUS DHAP FOLLOWED BY AUTOLOGOUS STEM CELL TRANSPLANTATION PLUS OBINUTUZUMAB MAINTENANCE PROVIDES A HIGH MRD RESPONSE RATE IN UNTREATED MCL PATIENTS, LYMA-101 TRIAL – A LYSA TRIAL
26 ledna, 2021 8:53 pmAuthor(s): S. Legouill, A. Beldi-Ferchiou, V. Cacheux, M. Alcantara, G. Salles, et al. EHA Library. Le Gouill S. Jun 14,...